| Title |
Efficacy and Safety of Lisdexamfetamine Dimesylate and Atomoxetine in the Treatment of Attention-Deficit/Hyperactivity Disorder: a Head-to-Head, Randomized, Double-Blind, Phase IIIb Study
|
|---|---|
| Published in |
CNS Drugs, August 2013
|
| DOI | 10.1007/s40263-013-0104-8 |
| Pubmed ID | |
| Authors |
Ralf W. Dittmann, Esther Cardo, Peter Nagy, Colleen S. Anderson, Ralph Bloomfield, Beatriz Caballero, Nicholas Higgins, Paul Hodgkins, Andrew Lyne, Richard Civil, David Coghill |
| Abstract |
The aim of this study was to compare the efficacy and safety of the prodrug psychostimulant lisdexamfetamine dimesylate (LDX) and the non-stimulant noradrenergic compound atomoxetine (ATX) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who had previously responded inadequately to methylphenidate (MPH). |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 173 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 2% |
| Brazil | 3 | 2% |
| Spain | 1 | <1% |
| United Kingdom | 1 | <1% |
| Unknown | 164 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 30 | 17% |
| Student > Master | 23 | 13% |
| Student > Bachelor | 22 | 13% |
| Student > Doctoral Student | 15 | 9% |
| Other | 14 | 8% |
| Other | 36 | 21% |
| Unknown | 33 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 51 | 29% |
| Psychology | 27 | 16% |
| Nursing and Health Professions | 11 | 6% |
| Neuroscience | 9 | 5% |
| Economics, Econometrics and Finance | 5 | 3% |
| Other | 28 | 16% |
| Unknown | 42 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 June 2021.
All research outputs
#4,764,144
of 23,613,071 outputs
Outputs from CNS Drugs
#437
of 1,329 outputs
Outputs of similar age
#40,256
of 200,137 outputs
Outputs of similar age from CNS Drugs
#5
of 15 outputs
Altmetric has tracked 23,613,071 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,329 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.5. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 200,137 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.